Skip to main content
NIH funding notice PA-19-033

Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)

Closed on September 5, 2021.

Posted
October 24, 2018
Close date
September 5, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $222,717 in first-year total cost, median $222,717.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 OTC-H (13)]1

Most frequent institutions

  1. SPECTRAGENETICS1
Competing awards under PA-19-033 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Highly multiplexed live-cell GPCR arrays for drug discovery in glioma.1R41CA257114-01JARVIK, JONATHAN WSPECTRAGENETICS, PA$222,717ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.